

CORRECTION

Open Access



Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody

Chad J. Swanson¹, Yong Zhang¹, Shobha Dhadha¹, Jinping Wang¹, June Kaplow¹, Robert Y. K. Lai², Lars Lannfelt^{3,4}, Heather Bradley¹, Martin Rabe¹, Akihiko Koyama¹, Larisa Reyderman¹, Donald A. Berry⁵, Scott Berry⁵, Robert Gordon², Lynn D. Kramer¹ and Jeffrey L. Cummings^{6*}

Correction: Alz Res Therapy 13, 80 (2021)
<https://doi.org/10.1186/s13195-021-00813-8>

Published online: 21 May 2022

Following the publication of the original article [1] files for Supplementary Appendices A and B were not included in the publication of the original article.

Supplementary Appendix A: Study Protocol (Supplementary Appendix A.pdf)

Supplementary Appendix B: Simulation Plan (Supplementary Appendix B.pdf)

The original article [1] has been updated.

Reference

1. Swanson CJ, Zhang Y, Dhadha S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. *Alz Res Therapy*. 2021;13:80 <https://doi.org/10.1186/s13195-021-00813-8>.

The original article can be found online at <https://doi.org/10.1186/s13195-021-00813-8>.

*Correspondence:

Jeffrey L. Cummings

jcumings@cnsinnovations.com

¹ Eisai Inc., Woodcliff Lake, NJ, USA

² Eisai Ltd., Hatfield, UK

³ BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden

⁴ Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden

⁵ Berry Consultants, LLC, Austin, TX, USA

⁶ Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA



© The Author(s) 2022, corrected publication 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.